Aravive Inc to Discuss AVB-500 Phase 1b Study Updates Conference Call Transcript
Good morning, and welcome to Aravive conference call to discuss this morning's announcement of data. Please be advised that this call is being recorded at Aravive's request. I would now like to turn the call over to Christina Tartaglia with Stern Investor Relations. You may begin.
Thank you, and good morning, everyone. This morning, we issued a press release outlining updated data from our ongoing Phase Ib study of AVB-500 in platinum-resistant ovarian cancer patients. Our press release and accompanying corporate deck which we will be referring to can be found in the Investors and Media section of our website. Jay Shepard, Aravive's Chief Executive Officer; and Dr. Gail McIntyre, Aravive's Chief Scientific Officer, will be providing an overview of this data today. Additionally, Vinay Shah, Aravive's Chief Financial Officer, is also on the phone with us and will be available for Q&A following today's remarks.
Today's discussion will include forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |